ArticleClinical journal of gastroenterology2026

Durvalumab and tremelimumab combination therapy achieved remarkable response in primary hepatic undifferentiated carcinoma with high PD-L1 expression.

Michihiko Kawahara et al.PubMed ↗Publisher ↗

No numbers read from the abstract.